Prof Josef Vormoor talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the management of relapsed T-ALL in paediatrics.

Prof Vormoor explains that one of the clinical questions currently is that: if you inhibit the RAS pathway in patients with gene mutations and combine this with dexamethasone, do we see a signal that allows us to progress with more frontline treatment?

He outlines that this trial with the RAS pathway is open to children.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.